- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00003215
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with more than one drug regimen may kill more tumor cells. It is not known whether receiving standard combination chemotherapy alone is more effective than receiving multiple combination chemotherapy plus peripheral stem cell transplantation for aggressive non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is comparing giving different combination chemotherapy regimens together with peripheral stem cell transplantation to see how well they work in treating patients with newly diagnosed aggressive non-Hodgkin's lymphoma.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: cyclophosphamide
- Médicament: leucovorine calcique
- Radiation: Radiothérapie
- Médicament: chlorhydrate de mitoxantrone
- Médicament: prednisone
- Médicament: la cytarabine
- Médicament: étoposide
- Médicament: méthotrexate
- Médicament: méthylprednisolone
- Médicament: hydrocortisone thérapeutique
- Médicament: sulfate de vincristine
- Médicament: chlorhydrate de doxorubicine
- Procédure: greffe de cellules souches du sang périphérique
- Biologique: filgrastim
- Médicament: melphalan
- Médicament: Régime CHOP
- Procédure: ablation de la moelle osseuse avec support de cellules souches
Description détaillée
OBJECTIVES:
- Compare the efficacy of sequential high-dose chemotherapy and autologous peripheral blood stem cell transplantation with standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with newly diagnosed aggressive non-Hodgkin's lymphoma and poor prognostic factors.
- Compare the toxic effects of these 2 regimens in these patients.
- Compare the response rates and overall survival of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive standard chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Patients receive cyclophosphamide IV over 30 minutes, doxorubicin IV, and vincristine IV on day 1. Patients receive oral prednisone daily on days 1-5. Treatment repeats every 21 days for 6-8 courses. Patients with bulky disease at diagnosis or residual disease after chemotherapy receive radiotherapy 30-60 days after initiation of the last course of CHOP.
Arm II: Patients receive 5 regimens of chemotherapy administered in sequence.
- Regimen A : Patients receive CHOP as in Arm I.
- Regimen B: Three weeks after starting regimen A, patients receive high-dose cyclophosphamide IV over 24 hours on day 1. Patients without initial bone marrow involvement receive filgrastim (G-CSF) subcutaneously (SC) daily beginning on day 3 and continuing until autologous peripheral blood stem cells (PBSC) are harvested. PBSC are harvested on days 13-15 or when blood counts recover. Patients with initial bone marrow involvement do not undergo harvest of PBSC at this time, but receive G-CSF SC daily.
- Regimen C: Two to three weeks after high-dose cyclophosphamide, patients receive vincristine IV and high-dose methotrexate IV over 6 hours on day 2. Patients receive leucovorin calcium IV every 6 hours on days 3-5 beginning 24 hours after initiation of the methotrexate infusion.
- Regimen D: Within 1-2 weeks after the administration of methotrexate in regimen C, patients receive methylprednisolone IV followed 6 hours later by high-dose etoposide IV over 10 hours on day 1. Patients receive methylprednisolone IV on day 2. Patients without initial bone marrow involvement receive G-CSF SC daily beginning on day 3 and continuing until blood counts recover. Patients with initial bone marrow involvement receive G-CSF SC daily until autologous PBSC are harvested. PBSC are harvested on days 10-14 or when blood counts recover.
- Regimen E: Myeloablative therapy and autologous PBSC transplantation begin 16-40 days after the administration of etoposide. Patients receive mitoxantrone IV over 1 hour every 2 hours for 3 doses on day 2 and melphalan IV over 30 minutes on day 5. PBSC are reinfused on day 6 beginning at least 24 hours after the administration of melphalan. Patients receive G-CSF SC or by continuous infusion beginning on day 7.
Patients with bulky disease at diagnosis or residual disease after chemotherapy receive radiotherapy 30-100 days after PBSC transplantation.
Patients at high risk of developing CNS disease receive prophylactic intrathecal chemotherapy. Patients may receive cytarabine, methotrexate, and hydrocortisone or methotrexate and hydrocortisone every 1-2 weeks for 6 courses.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 400 patients will be accrued for this study within 4-5 years.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Wiesbaden, Allemagne, D-65199
- Dr. Horst-Schmidt-Kliniken
-
-
-
-
-
Athens, Grèce, 11522
- Saint Savvas Cancer Hospital of Athens
-
-
-
-
-
Milano, Italie, 20141
- European Institute of Oncology
-
-
-
-
-
Vienna, L'Autriche, A-1090
- Allgemeines Krankenhaus der Stadt Wien
-
-
-
-
-
Basel, Suisse, CH-4031
- Universitatsspital-Basel
-
Bellinzona, Suisse, CH-6500
- Oncology Institute of Southern Switzerland
-
Bern, Suisse, CH-3010
- Inselspital, Bern
-
Chur, Suisse, CH-7000
- Ratisches Kantons und Regionalspital
-
Collonge-Bellerive, Suisse, CH-1245
- Hôpital Cantonal Universitaire de Genève
-
Lausanne, Suisse, 1011
- Centre Hospitalier Universitaire Vaudois
-
St. Gallen, Suisse, CH-9007
- Kantonsspital - St. Gallen
-
Zurich, Suisse, CH-8008
- Klinik Hirslanden
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL)
- Diffuse large B-cell lymphoma
- Primary mediastinal large B-cell lymphoma
- Anaplastic large cell lymphoma (B-cell, T-cell, or null-cell type)
At least two of the following risk factors:
- Stage III or IV
- LDH greater than upper limit of normal (ULN)
- ECOG 2, 3, or 4
- No CNS involvement
PATIENT CHARACTERISTICS:
Age:
- 18 to 60
Performance status:
- See Disease Characteristics
- ECOG 0-4
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- No hepatitis B or C
- AST or ALT no greater than 2 times ULN*
- Bilirubin no greater than 2.34 mg/dL* NOTE: *Unless due to tumor involvement
Renal:
- Creatinine clearance at least 60 mL/min (unless due to tumor involvement)
Cardiovascular:
- No significant heart failure
- LVEF normal
- No active angina pectoris
- No myocardial infarction within the past 6 months
- No major ventricular arrhythmia
Pulmonary:
- No significant lung disorder
Other:
- HIV negative
- No severe active acute or chronic infection
- No severe psychoses
- No prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix or nonmelanomatous skin cancer
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy for NHL (except emergency therapy, but no more than 1 course of standard chemotherapy)
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy for NHL (except emergency therapy of no greater than 600 cGy radiation)
- No concurrent prophylactic radiotherapy to the brain
Surgery:
- Not specified
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Daniel C. Betticher, MD, University Hospital Inselspital, Berne
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Lymphome diffus à grandes cellules de stade III chez l'adulte
- Lymphome immunoblastique à grandes cellules de stade III de l'adulte
- Lymphome diffus à grandes cellules de stade IV chez l'adulte
- Lymphome immunoblastique à grandes cellules de stade IV de l'adulte
- Lymphome diffus à cellules mixtes adulte de stade III
- Lymphome diffus à cellules mixtes adulte de stade IV
- lymphome anaplasique à grandes cellules
- Lymphome diffus à grandes cellules non contigu de stade II de l'adulte
- Lymphome diffus à cellules mixtes non contigu de stade II de l'adulte
- Lymphome immunoblastique à grandes cellules non contigu de stade II de l'adulte
- Lymphome immunoblastique à grandes cellules contigu de stade II de l'adulte
- Lymphome immunoblastique à grandes cellules de stade I de l'adulte
- Lymphome diffus à grandes cellules contigu de stade II chez l'adulte
- Lymphome diffus à cellules mixtes adulte de stade II contigu
- Lymphome diffus à grandes cellules de stade I de l'adulte
- Lymphome diffus à cellules mixtes adulte de stade I
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Tumeurs
- Troubles lymphoprolifératifs
- Maladies lymphatiques
- Troubles immunoprolifératifs
- Lymphome
- Lymphome non hodgkinien
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Agents autonomes
- Agents du système nerveux périphérique
- Agents antiviraux
- Inhibiteurs de la synthèse des acides nucléiques
- Inhibiteurs d'enzymes
- Analgésiques
- Agents du système sensoriel
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Antiémétiques
- Agents gastro-intestinaux
- Glucocorticoïdes
- Les hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Agents antinéoplasiques, hormonaux
- Agents neuroprotecteurs
- Agents protecteurs
- Agents antinéoplasiques, alkylants
- Agents d'alkylation
- Agonistes myéloablatifs
- Agents antinéoplasiques phytogéniques
- Inhibiteurs de la topoisomérase II
- Inhibiteurs de la topoisomérase
- Agents dermatologiques
- Micronutriments
- Antibiotiques, Antinéoplasiques
- Vitamines
- Agents de contrôle de la reproduction
- Antidotes
- Complexe de vitamine B
- Agents abortifs, non stéroïdiens
- Agents abortifs
- Antagonistes de l'acide folique
- Méthylprednisolone
- Cyclophosphamide
- Étoposide
- Leucovorine
- Lévoleucovorine
- Prednisone
- Melphalan
- Doxorubicine
- Doxorubicine liposomale
- Cytarabine
- Méthotrexate
- Vincristine
- Mitoxantrone
- Hydrocortisone
- Hydrocortisone 17-butyrate 21-propionate
- Acétate d'hydrocortisone
- Hémisuccinate d'hydrocortisone
Autres numéros d'identification d'étude
- SAKK 38/97
- SWS-SAKK-38/97
- EU-97037
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .